Skip to main content
. 2021 May 14;17(1):69–82. doi: 10.5114/wiitm.2021.106126

Table III.

Surgical related information

Study The Same time period Group N FIGO stage Lymph node metastasis Patients treated with adjuvant radiotherapy Rate of positive margins Removed lymph nodes Team of operations Type of surgery
Choi 2012 Yes LARVH 89 3/11/73/2 (IA1/IA2/IB1/IIA) 4 (4.5%) 0 0 19.5 ±6.2 1 surgeon (DSB) 3 II, 86 III
ARH 99 1/8/83/7 (IA1/IA2/IB1/IIA) 7 (7.1%) 0 0 20.4 ±7.7 1 surgeon (JHL) 9 II, 90 III
Gortchev 2012 Yes LARVH 46 46 IB1 5 (10.9%)/ NR NR 11.3 ±5.2 1 surgeon Type III
ARH 175 175 IB1 42 (24.0%) NR NR 15.9 ±7.7 2 surgeon
Hou 2011 Yes LARVH 33 4/10/15/4 (IA/IB/IIA/IIB) 0 NR NR 19.74 ±7.43 The same group of surgeons NR
ARH 30 2/10/14/4 (IA/IB/IIA/IIB) 0 NR NR 20.35 ±6.62
Jackson 2004 Yes LARVH 50 2/47/1 (IA2/IB1/IB2) 1 (2%) 7 (14%) 5 (10%) Median 15 The same group of surgeons NR
ARH 50 2/47/1 (IA2/IB1/IB2) 1 (2%) 2 (4%) 1 (2%) Median 16
Malur 2001 No LARVH 70 3/13/41/3/9/1/0 (IA1/IA2/IB/IIA/IIB/IIIA/IIIB) NR NR NR 27 (10–56)# Senior registrars Type II
ARH 70 1/1/51/5/11/0/1 (IA1/IA2/IB/IIA/IIB/IIIA/IIIB) NR 100% NR 10.7 (0–26)
Morgan 2007 Yes LARVH 30 9/21/0/0 (IA/IB/IIA/IIB) 0 1 (3.3%) NR 14.8 (3–37)# The same group of surgeons Type III
ARH 30 2/24/2/2 (IA/IB/IIA/IIB) 5 (16.7%) 2 (6.7%) NR 17.4 (6–36)
Naik 2010 Yes LARVH 7 7 IB1 2 (28.57%) 2 (28.57%) 1 (14.29%) 14 (12–19)# The same group of surgeons NR
ARH 6 6 IB1 1 (16.7%) 1 (16.7%) 0 (0.0%) 12 (11–14)
Pahisa 2010 No LARVH 67 3/61/3 (IA2/IB1/IIA) 7 (10.4%) 12 (17.9%) 0 15.8 (10–33)# J.P, S.M–R, or A.T. NR
ARH 23 2/21/0 (IA2/IB1/IIA) 3 (13.0%) 5 (21.7%) 0 12.4 (8–27)
Papacharalabous 2009 Yes LARVH 14 14 (IA2–IB) 1 (7.7%) 1 (7.7%) 0 22.4 ±10.6 S.BM NR
ARH 12 12 (IA2–IB) 2 (16.7%) 5 (41.67%) 0 21.5 ±12.8 A.T or S.BM
Sharma 2006 Yes LARVH 27 27/0 (IB1/IB2) 0 (0.0%) 0 (0.0%) 0 23.5 (7–62)# J.BM NR
ARH 28 23/5 (IB1/IB2) 2 (7.1%) 2 (7.1%) 0 27.6 (13–57) J.BM and R.SA
Steed 2004 Yes LARVH 71 14/10/46/1 (IA1/IA2/IB1/IB2) 5 (7.0%) 16 (22.5%) 1 (1.4%) NR One surgeon NR
ARH 205 29/11/148/17 (IA1/IA2/IB1/IB2) 19 (9.3%) 43 (21.0%) 6 (2.9%) NR Six surgeons
Yu 2013 Yes LARVH 40 12/17/9/2 (IA2/IB1/IB2/IIA) 0 (0.0%) 1 (2.5%) 0 21.4 (18–28)# The same group of surgeons NR
ARH 40 6/15/13/6 (IA2/IB1/IB2/IIA) 5 (12.5%) 2 (5.0%) 0 27.3 (19–32)
Zhang 2017 Yes LARVH 35 4/13/10/6/2 (IA2/IB1/IB2/IIA/IIB) NR 20 (57.14%) NR 23.71 ±9.45 The same 2 gynaecological oncology surgeons Type III
ARH 42 2/20/8/8/4 (IA2/IB1/IB2/IIA/IIB) NR 24 (57.14%) NR 36.19 ±12.28

NR – not reported, FIGO – International Federation of Gynaecology and Obstetrics

#

mean (range).